[{"orgOrder":0,"company":"Tessara Therapeutics","sponsor":"CRC-P","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Small molecule","year":"2024","type":"Funding","leadProduct":"Neuroplastogen","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Tessara Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Tessara Therapeutics \/ CRC-P","highestDevelopmentStatusID":"12","companyTruncated":"Tessara Therapeutics \/ CRC-P"}]

Find Clinical Drug Pipeline Developments & Deals by Tessara Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will focus on the development of neuroplastogens for the treatment of substance use disorders, with an emphasis on methamphetamine addiction.

                          Brand Name : Undisclosed

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 28, 2024

                          Lead Product(s) : Neuroplastogen

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Discovery

                          Sponsor : CRC-P

                          Deal Size : $3.0 million

                          Deal Type : Funding

                          blank